scholarly journals Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

2019 ◽  
Vol 8 (4) ◽  
pp. 1389-1400 ◽  
Author(s):  
Linghong Guo ◽  
Yuanyuan Hu ◽  
Xi Chen ◽  
Qingfang Li ◽  
Benling Wei ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Cyclin Dependent Kinases ◽  
Efficacy Profile

scholarly journals Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis

Oncotarget ◽  
2016 ◽  
Vol 7 (28) ◽  
pp. 44545-44557 ◽  
Author(s):  
Chenjing Zhu ◽  
Xuelei Ma ◽  
Yuanyuan Hu ◽  
Linghong Guo ◽  
Bo Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Therapy ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Efficacy Profile

Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

2018 ◽  
Vol 39 (1) ◽  
pp. 27-43 ◽  
Author(s):  
Zhihang Tao ◽  
Stanley Xiangyu Li ◽  
Kai Shen ◽  
Yunuo Zhao ◽  
Hao Zeng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Meta Analysis ◽  
Safety And Efficacy ◽  
Efficacy Profile

Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials

2018 ◽  
Vol 56 (10) ◽  
pp. 1110-1119 ◽  
Author(s):  
Yazan Zayed ◽  
Babikir Kheiri ◽  
Momen Banifadel ◽  
Michael Hicks ◽  
Ahmed Aburahma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Uncontrolled Asthma ◽  
Safety And Efficacy

scholarly journals Safety and efficacy of the oblique-axis plane in ultrasound-guided internal jugular vein puncture: A meta-analysis

2018 ◽  
Vol 46 (7) ◽  
pp. 2587-2594 ◽  
Author(s):  
Shuai Miao ◽  
Xiuli Wang ◽  
Lan Zou ◽  
Ye Zhao ◽  
Guanglei Wang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Success Rate ◽  
Internal Jugular Vein ◽  
Randomized Clinical Trials ◽  
Jugular Vein ◽  
Meta Analysis ◽  
Short Axis ◽  
Ultrasound Guided ◽  
Safety And Efficacy ◽  
First Pass

Objective This meta-analysis was performed to evaluate the safety and efficacy of the oblique-axis plane in ultrasound-guided internal jugular vein puncture. Methods We searched Embase, PubMed, the Cochrane Library, Web of Science, and China National Knowledge Infrastructure for relevant randomized clinical trials comparing the oblique axis with the short axis in ultrasound-guided internal jugular vein puncture. Results Five randomized clinical trials were included in this meta-analysis. The pooled meta-analysis showed that the incidence of arterial puncture in the oblique-axis group was significantly lower than that in the short-axis group. No significant difference was found in the first-pass success rate between the oblique-axis group and short-axis group. Additionally, there were no significant differences in the puncture success rate or number of attempts required between the two groups. Conclusion Ultrasound-guided internal jugular vein puncture using the oblique-axis plane reduced the risk of arterial puncture, but no difference was found in the first-pass success rate, puncture success rate, or number of attempts required.

scholarly journals Safety and Efficacy in Relapsed or Refractory Classic Hodgkin’s Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-13 ◽  
Author(s):  
Xueyan Zhang ◽  
Li Chen ◽  
Yawei Zhao ◽  
Huiru Yin ◽  
He Ma ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Immune Checkpoint ◽  
Hodgkin’S Lymphoma ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Survival Rates ◽  
Hodgkin's Lymphoma ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Safety And Efficacy

Background. Classic Hodgkin’s lymphoma (cHL) is characterized by the unique biology in which rare Hodgkin-Reed-Sternberg cells propagate an immunosuppressive microenvironment. Checkpoint inhibitors that target the interaction of PD-1 immune checkpoint receptors have demonstrated remarkable activities in various cancers, such as cHL. This study aims to evaluate the safety and efficacy of PD-1 inhibitors in treating relapsed or refractory cHL (rrHL). Methods. We searched PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Wanfang, Chinese Biological Medical Literature, and Abstracts of Conference proceedings of annual meetings without any language restrictions to limit language bias (up to January 2019) for prospective clinical trials that evaluate PD-1 inhibitors in treating relapsed or refractory cHL. Results. A total of 9 prospective clinical trials with 731 patients were included in the meta-analysis. The pooled risks of all-grade and grade ≥3 adverse events (AEs) were 0.86 (95% CI: 0.66–0.98) and 0.21 (95% CI: 0.17–0.24), respectively. The pooled response, complete response, partial response, and stable disease rates were 0.74 (95% CI: 0.70–0.79), 0.24 (95% CI: 0.18–0.34), 0.48 (95% CI: 0.41–0.55), and 0.15 (95% CI: 0.12–0.17), respectively. The pooled 6-month progression-free survival and 1-year overall survival rates were 0.76 (95% CI: 0.72–0.79) and 0.93 (95% CI: 0.90–0.96), correspondingly. Conclusions. Our meta-analysis suggested that anti-PD1 monoclonal antibodies improve the outcomes of response and survival rates with tolerable AEs in cHL. However, evidence of immune checkpoint inhibitors for patients with cHL remained insufficient. Well-designed randomized controlled trials or at least nonrandomized trials with a control group should be conducted to confirm the findings of this meta-analysis.

scholarly journals Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials

2001 ◽  
Vol 93 (16) ◽  
pp. 1204-1214 ◽  
Author(s):  
J. Seidenfeld ◽  
M. Piper ◽  
C. Flamm ◽  
V. Hasselblad ◽  
J. O. Armitage ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Cancer Therapy ◽  
Meta Analysis ◽  
Controlled Clinical Trials

scholarly journals Cannabidiol and the Management of Pediatric Neurological Disorders: A Systematic Review

2021 ◽  
Author(s):  
Caio de Almeida Lellis ◽  
Marco Alejandro Menacho Herbas ◽  
João Cesar Pereira da Cunha ◽  
Samyla Coutinho Paniago ◽  
Paulo Sérgio Machado Diniz
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Neurological Disorders ◽  
Pediatric Patients ◽  
Meta Analysis ◽  
Dravet Syndrome ◽  
Motor Disorder ◽  
Safety And Efficacy ◽  
Catholic University ◽  
Complex Motor

Introduction: Due to an increase in cases of neurological disorders refractory to conventional treatments in pediatrics patients, other therapies have been sought. Objectives: To analyze the safety and efficacy of CBD in the management of neurological disorders in children. Design and setting: A systematic review conducted at the Pontifical Catholic University of Goiás. Methods: This is a systematic review carried out in PubMed, Lilacs and MedLine databases, with the descriptors: “(Pediatric OR Neurology) AND (Cannabidiol OR Cannabis)”, being selected only the randomized studies, meta-analysis and clinical trials published in the last 10 years. Results: One randomized trial concluded that daily oral CBD solution reduced the frequency of seizures in pediatric patients with Lennox-Gastaut syndrome (LGS). In addition, another study concluded that CBD (20 mg/kg/day) is associated with up to a 50% decrease in seizures in children with SLG and Dravet syndrome. Furthermore, it was pointed out that the association of oral CBD (2 to 5 mg/kg/day) with antiepileptic drugs caused a mean reduction of 36.5% of severe seizures. Finally, CBD enriched with 0.25% THC reduced spasticity, dystonia and pain intensity in children with complex motor disorder. Conclusion: CBD was shown to be safe and effective as a treatment for refractory epilepsies and complex motor disorder in pediatric patients, with no serious side effects reported.

Sign in / Sign up

Export Citation Format

Share Document